May 5, 2020
Vifor Pharma’s partner Akebia with positive cardiovascular outcomes program testing vadadustat,
Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 5, 2020
Incyte posts Q1 2020 product, royalty revenues of $569M
Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019).
May 5, 2020
Bicycle Therapeutics doses first patient in Phase I dose escalation of its toxin conjugate with Nivolumab
– Monotherapy Phase I dose escalation remains ongoing; BT5528 appears well-tolerated as dosing approaches clinically relevant levels – BT5528 is…
May 5, 2020
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Merck is Proud to Make New Commitment in Support of #GivingTuesdayNow More than $30 Million Committed to COVID-19 Relief Efforts…
May 5, 2020
Pfizer, BioNTech in first doses in U.S. in global COVID-19 vaccine making
First participants have been dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.
May 5, 2020
Invicro LLC to Establish a Repository of Medical Image Datasets for COVID-19 Research
BOSTON–(BUSINESS WIRE)–#Johnshopkins—Invicro LLC, a Konica Minolta company, is working with Microsoft to create a free repository of COVID-19 diagnostic CT…
May 5, 2020
Athersys enrolls patients testing MultiStem cell therapy for COVID-19 induced ARDS
Athersys started enrollment of patients testing MultiStem cell therapy in a rapid advancement of clinical program for the treatment of ARDS based on prior clinical data reflecting favorable tolerability data and meaningful benefits on mortality, ventilator-free days and ICU-days
May 5, 2020
ICON appoints new Chief Medical Officer
ICON has appointed Dr. Kristen K. Buck as the new Chief Medical Officer (CMO), who joined from Optum Insights .
May 5, 2020
Crescendo, Cancer Research UK to develop novel bispecific Humabody therapeutic
Cancer Research UK’s Centre for Drug Development will fund Phase I clinical trial in solid tumours, Crescendo’s novel bispecific Humabody immunotherapies, CB213.
May 5, 2020
Cycle Pharmaceuticals, Medherant team up to make medicines with TEPI Patch technology
Cycle Pharmaceuticals and Medherant have signed an agreement to develop and commercialize medicines for rare diseases using the TEPI Patch technology.